Health Catalyst, Inc. (NASDAQ:HCAT) COO Sells $76,397.04 in Stock

Health Catalyst, Inc. (NASDAQ:HCAT) COO Daniel Lesueur sold 16,902 shares of the firm’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $4.52, for a total value of $76,397.04. Following the completion of the transaction, the chief operating officer now owns 216,250 shares in the company, valued at $977,450. The trade was a 7.25 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Daniel Lesueur also recently made the following trade(s):

• On Wednesday, February 5th, Daniel Lesueur sold 5,209 shares of Health Catalyst stock. The stock was sold at an average price of $5.76, for a total value of $30,003.84.
• On Monday, January 6th, Daniel Lesueur sold 5,209 shares of Health Catalyst stock. The stock was sold at an average price of $7.51, for a total value of $39,119.59.

Health Catalyst Stock Performance

Shares of HCAT stock opened at $4.43 on Thursday. The business’s 50-day moving average price is $5.56 and its 200-day moving average price is $7.10. Health Catalyst, Inc. has a 12 month low of $3.76 and a 12 month high of $9.24. The firm has a market capitalization of $311.03 million, a price-to-earnings ratio of -3.28 and a beta of 1.41. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32.

Analysts Set New Price Targets

A number of brokerages recently commented on HCAT. KeyCorp upgraded Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price target on the stock in a research report on Wednesday, January 8th. Canaccord Genuity Group decreased their price target on Health Catalyst from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, January 21st. Stifel Nicolaus decreased their price target on Health Catalyst from $10.00 to $5.00 and set a “hold” rating on the stock in a research report on Thursday, February 27th. Wells Fargo & Company reduced their price objective on Health Catalyst from $13.00 to $10.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 21st. Finally, Stephens reduced their price objective on Health Catalyst from $7.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 6th. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $9.27.

Institutional Trading of Health Catalyst

Hedge funds have recently made changes to their positions in the company. Group One Trading LLC raised its position in shares of Health Catalyst by 107.6% during the fourth quarter. Group One Trading LLC now owns 4,360 shares of the company’s stock worth $31,000 after acquiring an additional 2,260 shares during the last quarter. Creative Planning increased its holdings in Health Catalyst by 13.2% in the third quarter. Creative Planning now owns 21,348 shares of the company’s stock worth $174,000 after purchasing an additional 2,486 shares in the last quarter. Two Sigma Securities LLC increased its holdings in Health Catalyst by 19.5% in the fourth quarter. Two Sigma Securities LLC now owns 17,510 shares of the company’s stock worth $124,000 after purchasing an additional 2,862 shares in the last quarter. Legato Capital Management LLC increased its holdings in Health Catalyst by 3.7% in the fourth quarter. Legato Capital Management LLC now owns 87,992 shares of the company’s stock worth $622,000 after purchasing an additional 3,171 shares in the last quarter. Finally, Quantbot Technologies LP bought a new stake in Health Catalyst in the fourth quarter worth approximately $29,000. 85.00% of the stock is owned by institutional investors and hedge funds.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.